This application proposes continuation of a broadly-based program for mentoring junior investigators in AIDS-related patient-oriented research. This proposal builds on existing resources of the Division of Infectious Diseases at Brigham &Women's Hospital, including an NIH-funded Adult AIDS Clinical Trials Unit, an Adult ACTG Virology Support Laboratory, the Harvard Medical School Center for AIDS Research, NIH-funded institutional AIDS training grants, and R01-funded research of the applicant. Clinical and research fellows as well as junior faculty interested in pursuing careers in retroviral therapeutics and translational virology will be mentored by the applicant. Course work in molecular biology, biostatistics, HIV-1 medicine, clinical trials design, responsible conduct of research and the ethics of human research will be offered. The research component of this proposal focuses on clinical investigation and formal clinical trials of HIV-1 therapeutics, drug resistance, and viral fitness. Ongoing patient-oriented research under the applicants direction comprises an array of studies with the overall goal of developing novel therapeutic approaches for the treatment of HIV-1 infection, and understanding the interplay between drug resistance, immune escape, and viral fitness. Specific research aims of this proposal are 1) to characterize CCR5 affinity, co-receptor tropism, and fitness of HIV-1 variants resistant to the CCR5 inhibitor SCH-417690 that emerge in subjects participating in a phase 2 trial of this drug (ACTG protocol A5211);2) to characterize the fitness of immune escape mutants arising during the analytic treatment interruption phase of therapeutic vaccine trial (ACTG protocol A5197);and 3) to determine the influence of the HLA A*0201 allele on the rate of reversion of protease inhibitor resistance mutations in subjects interrupting a failing protease inhibitor. This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on critical issues in HIV-1 medicine.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Wilde, David B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Marconi, Vincent C; Wu, Baohua; Hampton, Jane et al. (2013) Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. AIDS Patient Care STDS 27:657-68
Li, Jonathan Z; Paredes, Roger; Ribaudo, Heather J et al. (2013) Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 207:893-7
Murphy, Richard A; Sunpath, Henry; Castilla, Carmen et al. (2012) Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 61:158-163
Putcharoen, Opass; Lee, Sun Hee; Henrich, Timothy J et al. (2012) HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 86:1119-28
Li, Jonathan Z; Brumme, Chanson J; Lederman, Michael M et al. (2012) Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One 7:e34134
Levison, Julie H; Orrell, Catherine; Gallien, S├ębastien et al. (2012) Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 7:e32144
Li, Jonathan Z; Paredes, Roger; Ribaudo, Heather J et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26:185-92
Tsibris, Athe M N; Hu, Zixin; Paredes, Roger et al. (2012) Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 86:6416-26
Sunpath, Henry; Wu, Baohua; Gordon, Michelle et al. (2012) High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 26:1679-84
Henrich, Timothy J; Lewine, Nicolas R P; Lee, Sun-Hee et al. (2012) Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother 56:1931-5

Showing the most recent 10 out of 72 publications